Microsoft Restores Microsoft 365 Services After Widespread Outage 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
LA JOLLA, Calif., May 08, 2017 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first quarter 2017 financial results after the close of U.S. financial markets on May 15, 2017. Kura Oncology’s management will host a webcast and conference call at 4:30 p.m. EDT/1:30 p.m. PDT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 877-516-3514 for domestic callers and 281-973-6129 for international callers and entering the conference code: 14001186. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 14001186.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849 5375 [email protected]
